Fredun Pharmaceuticals Limited has fixed June 23, 2026, as the record date for the payment of a final dividend for the financial year 2025-26. The company announced a dividend of 7% on equity shares with a face value of ₹10 each. This entitlement is subject to the approval of shareholders at the ensuing Annual General Meeting.

The record date of Tuesday, June 23, 2026, has been established to ascertain the members eligible for the payout. The dividend recommendation comes from the Board of Directors. If approved, the payment will be made within 30 days from the date of the Annual General Meeting, subject to the deduction of tax at source.

The intimation was submitted to BSE Limited pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was confirmed by Fredun Nariman Medhora, Managing Director of the company.

Dividend Details

Fredun Pharmaceuticals Limited has scheduled a revised earnings conference call to discuss its financial performance for the quarter ended Q4FY26. The meeting is set to take place on June 10, 2026, at 11:00 a.m., providing stakeholders with an opportunity to review the company's quarterly results and operational outlook.

The announcement was made in compliance with Regulation 30 read with sub-para 15, Para A Part A Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call will be led by the company's Managing Director, Fredun Medhora.

Participants can join the discussion using the universal dial-in numbers provided by the company. Registration is required to access the conference via the Diamond Pass link. Stakeholders are advised to dial in approximately 10 minutes prior to the scheduled start time to ensure timely connection.

Conference Call Details

Key Participants

• Fredun Medhora: Managing Director

The conference call facilitator, Kirin Advisors, noted that certain statements made during the session may constitute forward-looking statements. These are subject to risks and uncertainties, including changes in the economic environment, and actual results may differ materially from those expressed or implied.